Outcome of non-invasive domiciliary ventilation in elderly patients  by Farrero, Eva et al.
ARTICLE IN PRESS
Respiratory Medicine (2007) 101, 1068–10730954-6111/$ - see fr
doi:10.1016/j.rmed.
Corresponding au
E-mail address: eOutcome of non-invasive domiciliary
ventilation in elderly patients
Eva Farrero, Enric Prats, Frederic Manresa, Joan EscarrabillUFIS-Respiratoria, Servei de Pneumologia, Hospital Universitari de Bellvitge, Feixa Llarga s/n, L’Hospitelet de Llobregat,
Barcelona, Spain
Received 9 June 2006; accepted 1 October 2006
Available online 28 November 2006KEYWORDS
Non-invasive
ventilation;
Chronic hypercapnic
respiratory failure;
Domiciliary
treatment;
Elderlyont matter & 2006
2006.10.005
thor. Tel./fax: +3
farrero@csub.scs.Summary
Study objectives: To analyze the short- and long-term effects of domiciliary non-invasive
ventilation (NIV) in the elderly.
Methods: From 1990 to 2005 all patients who initiated NIV at age 75 or older were
included in the study. The mean follow-up period was 36 (24) months. Data were obtained
from a database record.
Results: Forty-three patients, mean age 77 (1.9) years and hypercapnic respiratory failure
secondary to restrictive, neuromuscular or hypoventilatory disease were included. The
short-term effects included a significant improvement in arterial blood gases and nocturnal
desaturations during NIV compared to baseline: PaO2 increased a mean of 19mmHg
ðPo0:0001Þ, PaCO2 decreased a mean of 16mmHg ðPo0:0001Þ and nocturnal time with
SaO2o90% decreased a mean of 72% ðPo0:0001Þ. Arterial blood gases while breathing
room air also improved significantly at 6 months after NIV initiation. Five patients (11%)
discontinued treatment; this group did not differ from patients who continued NIV. Mean
compliance was 8.3 (3.1) h/day. In the long-term effects, we observed that the initial
improvement of arterial blood gases breathing room air was maintained throughout the
followup period. The number of hospital admissions and days of hospital stay decreased
significantly (Po0:0001 and 0:001, respectively) after NIV initiation. The poorest survival
was observed in ALS patients (median 10.9 (2.3) months) significantly lower than the
survival for the other diagnostic groups (median 58.5 (4.8) months), P ¼ 0:0013.
Conclusions: NIV is an effective treatment in the elderly. It improves arterial blood gases
and nocturnal desaturations, decreases hospital admissions and is associated with long
survival. So advanced age should not be considered as an exclusion criteria to prescribe
NIV.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Over the last decade, domiciliary non-invasive ventilation
(NIV) has become a widely accepted treatment for chronic
respiratory failure due to chest wall disorders and neuro-
muscular diseases. Numerous uncontrolled studies have
been published supporting the efficacy of NIV for these
indications, and improvements have been observed in
daytime gas exchange, symptoms of hypoventilation, survi-
val, quality of life and length of hospital stays.1–5
The appearance of bilevel pressure ventilators and
improvements in nasal masks have increased patient
comfort and reduced adverse effects of NIV, but the
treatment can still be cumbersome and difficult for some
patients to tolerate. Furthermore, the open-circuit design
of NIV requires the patient’s cooperation and acceptance to
ensure treatment efficacy.6 For these reasons, and also
considering the lower life expectancy in elderly patients (75
years or above) with chronic respiratory insufficiency, NIV is
sometimes rejected as a therapeutic option in this group,
even though there is no specific mention of age among the
criteria for the indication of NIV.7
Very few data are available about the outcomes of NIV in
the elderly population, and to the best of our knowledge,
one short study only has been published, reporting data of
six patients.8
Treatment with home mechanical ventilation was in-
itiated in our center in 1990, and since then, NIV has been
prescribed to more than 500 patients with no age-related
restriction in its indications. However, as some patients have
abandoned treatment we were interested to know whether
we should modify our clinical practice. The aim of this study
was to evaluate the outcome—including short- and long-
term effects of NIV in our elderly patients, especially
concerning tolerance, compliance, efficacy of ventilation
and long-term results such as survival.
Methods
Patient selection and database
All patients who initiate NIV in our respiratory department
are included in a database which records the following data:
(a) assessment prior to the initiation of NIV, (b) efficacy of
ventilation at onset, and (c) prospective followup.
The present study includes all patients who started NIV at
75 years of older and who were included in our database
from January 1990 to December 2004. Patients were
followed up until death or until the end of the study in
December 2005. The mean followup was 36 (24) months.
The study was approved by the ethics committee of the
Hospital Universitari de Bellvitge and informed written
consent was obtained for each subject undergoing domicili-
ary NIV.
Initial assessment
Patients were evaluated in the outpatient clinic or during
hospital admission if NIV was initiated in an acute situation.
Data recorded in the database included: demographic data,
living arrangements, diagnosis, Charlson comorbidity index,9lung function tests (FVC and FEV1), arterial blood gas
analysis (PaO2 and PaCO2), and nocturnal oximetry while
breathing room air. Hospital admissions and number of days
spent in hospital in the year prior to the initiation of NIV
were also recorded.Initiation of ventilation
NIV was indicated for patients with restrictive thoracic and
neuromuscular disorders or hypoventilatory syndromes with
symptoms attributable to chronic hypoventilation (e.g.:
poor sleep quality, daytime hypersomnolence and morning
headache) or respiratory muscle weakness (ortopnea,
ineffective cough) and nocturnal desaturation or daytime
hypercapnia (PaCO2445mmHg). As mentioned above, no
restrictions were made in relation to age. Adaptation to
ventilation and adjustment of ventilator settings were
always done during an inpatient admission. The type of
ventilator and interface were selected based on the
patient’s comfort and adaptation, correction of gas-ex-
change abnormalities and the number of hours of ventila-
tion. Equipment used included volumetric ventilator (PLV-
100, Lifecares, Germany and PV 501, BREAS Medicals,
Sweden) or pressure ventilator (O’NYX, Pierre Medical S.A.,
France; BiPAP, Respironics Inc, Murrysville, PA and Sullivan
VPAP ST II, ResMed Ltd., UK). Interfaces included custom-
molded and commercial nasal masks with chin-strap to
minimize oral leaks.
Data recorded in the database included: type of venti-
lator and interface, ventilation parameters, arterial blood
gases during diurnal ventilation, and oxygen saturation
(SaO2) during nocturnal ventilation.Follow-up
Patients were closely followed up after NIV initiation with a
home visit during the week after hospital discharge, and an
outpatient clinic visit 1 month later. Subsequent visits were
made according to the patient’s stability, every 3 or 6
months. Visits were also established at the patient’s request
if symptoms worsened or in case of troubles with interfaces
or the ventilator.
External companies are responsible for servicing (main-
tenance, repair and delivery of consumables) the home
ventilators. Routine visits were carried out every 1–3 months
and the number of hours on the counters on ventilators were
recorded.
Data recorded in the database included: arterial blood
gases while breathing room air at each outpatient clinic
visit, compliance, admissions and days spent in hospital in
the year after initiation of NIV, and survival.Statistical analysis
Changes in arterial blood gases, nocturnal SaO2 and hospital
admissions after NIV were evaluated using the Student’s t-
test or Wilcoxon test to compare quantitative variables and
w2 test to compare qualitative variables. Data are reported
as mean (standard deviation).
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Table 1 Patients’ characteristics at baseline.
NIV elective NIV acute P
(n ¼ 36) (n ¼ 7)
Age (years) 76.8 (1.8) 77.8 (2.3) ns
PaO2 (mmHg) 56 (13) 45 (6) 0.05
PaCO2 (mmHg) 57 (11) 60 (12) 0.01
CT 90 (%) 74 (37) 100 (0) 0.03
FVC (% predicted) 47 (16) 53 (21) ns
FEV1 (% predicted) 45 (20) 43 (15) ns
Comorbidity
(Charlson)
2 (1.5) 2.1 (0.6) ns
Admission (year
before)
2.2 (2.3) 2 (0.8) ns
Hospital stay (days,
year before)
22 (25) 26 (8) ns
Table 2 Patients’ baseline characteristics according to
NIV tolerance.
Abandon NIV Continue NIV
Age (year) 76 (1.5) 77 (2)
Sex (men/women) 1/4 19/19
PaO2 (mmHg) 53 (12) 54 (13)
PaCO2 (mmHg) 64 (11) 59 (12)
CT 90 (%) 74 (37) 79 (35)
FVC (% predicted) 56 (18) 47 (16)
FEV1 (% predicted) 46 (12) 44 (20)
Comorbidity (Charlson) 2.6 (2.5) 2 (1.3)
E. Farrero et al.1070Analysis of survival was undertaken using the Kaplan–
Meier method, applying the Log rank test for differences
between groups.
Results
Patients
In total, 43 patients (23 women, 54%) with chronic
hypercapnic respiratory failure started domiciliary ventila-
tion at age 75 or above. Diagnosis included: kyphoscoliosis
11 (25%), post-tuberculosis sequellae 14 (33%), neuromus-
cular disease 9 (21%) [5 amyotrophic lateral sclerosis ALS],
hypoventilatory disorders 8 (19%) [5 related to obesity], and
bronchiectasies plus kyphosis 1 (2%). Ventilators used were:
a volume ventilator in 9 patients (21%), O’NYX in 4 patients
(9%), and bilevel pressure devices in 30 patients (70%).
Interfaces used were custom-molded nasal mask in 9
patients (21%) and commercial nasal masks in 34 patients
(79%).
The majority of patients (86%) lived with their family, 3
patients (7%) lived in a nursing home and 3 patients (7%)
lived alone.
Seven patients (16%) initiated NIV in acute situation and
36 patients (84%) initiated NIV electively. Patients’ char-
acteristics of both groups at onset of ventilation are shown
in Table 1. Among patients in acute situation, nocturnal
oximetry while breathing room air was not recorded in one
case due to severe hypoxemia and forced spirometry was
not recorded in 2 patients (5%) because of their clinical
severity. The results of forced spirometry were disregarded
in 6 patients (14%) of the elective group due to lack of
cooperation.
Tolerance, side effects and compliance
Five patients (11%) (4 women, 1 man), with a mean age of
76.4 (1.5) years, discontinued ventilation treatment at
between 1 week and 6 months. Their diagnoses were
kyphoscoliosis in 3 patients, post-tuberculosis sequelae in
1, and obesity-hypoventilation syndrome in 1. All five
presented markedly abnormal arterial blood gases (mean
PaO2 53.6 (12.7)mmHg, mean PaCO2 64.2 (11.3)mmHg,
mean percentage of time with SaO2o90% (CT 90) in
nocturnal oximetry 74 (37)%) when ventilation was started.
NIV efficacy was observed during the hospital stay with a
significant improvement both in blood gases and nocturnal
saturation during ventilation: mean PaO2 74.2 (5)mmHg,
mean PCO2 43 (3.5)mmHg, mean CT 90 0%. Adaptation and
tolerance to NIV was considered normal during hospital
admission and patients agreed to continue treatment at
home. Once home, however, they found it very uncomfor-
table, reported inability to sleep, and refused to continue
the therapy. No significant differences were observed in the
baseline characteristics between these five patients and the
group that continued with NIV (Table 2). The side effects
were rare in the group of patients who abandoned
treatment, only one patient presented skin eczema that
was easily resolved by changing the nasal mask. Among
patient who continued treatment, adverse effects were
observed in 22 patients (58%) being nasal skin lesions (26%)and rinitis with nasal dryness (16%) the more frequent. The
severity of side effects was minor and in no case forced us to
break off the treatment. On the contrary, the incidence and
type of side effects observed in the elderly was very similar
to that observed in our general population treated with NIV
for long term.10
The mean compliance of patients who continued NIV was
8.3 (3.1) h/day.
The efficacy of the treatment, and survival in this study
refer to patients ðn ¼ 38Þ that continued with NIV.Efficacy of ventilation
A significant improvement in diurnal arterial blood gases and
nocturnal SaO2 was observed when the patients were
receiving ventilation in comparison with the baseline
situation breathing room air. Because of possible effects of
the acute situation in the evolution of blood gases,11 we
analyzed separately data for patients that initiated NIV in
acute situation and for patients that started treatment
electively in stable situation. The magnitude of improve-
ment was similar in the acute and the elective patients,
although hypercapnia was not completely normalized during
ventilation in the acute group, Table 3.
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Figure 2 Comparison of survival between diagnosis.
Table 3 Efficacy of ventilation: comparison of diurnal gases and nocturnal oxymetry while breathing room air and with
ventilation.
NIV started elective NIV started in acute
Room air NIV P Room air NIV P
PaO2 (mmHg) 53.6 (12.3) 72 (11.4) 0.0001 45.8 (6) 68 (13) 0.01
PaCO2 (mmHg) 60 (13.3) 44.4 (6.7) 0.0001 69 (12.7) 51 (8) 0.01
CT 90% 81.3 (34.4) 9 (17) 0.0001 100 17 (25) 0.01
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Figure 1 Pattern of gases while breathing room air after
initiation of NIV. BS: baseline, 6M: 6 months, Y: year. Data shown
as mmHg. PaO2 A and PaCO2 A: patients that initiated NIV in
acute situation. PaO2 E and PaCO2 E: patients that initiated NIV
in elective situation.
Outcome of non-invasive domiciliary ventilation 1071Arterial blood gases while breathing room air also
improved after initiation of NIV and the improvement
remained over the followup period. The improvement,
specially for hypercapnia was more rapid in the patients
that initiated NIV in elective situation. Figure 1 plots the
evolution of the diurnal PaO2 and PaCO2 while breathing
room air for both groups.
Eighteen patients (47%) were on previous long-term
oxygen therapy (LTOT). After initiation of NIV, LTOT was
withdrawn in 5 patients (28%). Thirteen continued to have
additional oxygen during the night because of nocturnal
desaturations, related in most cases to oral leaks that could
not be avoided in spite of the efforts to improved efficacy of
nocturnal ventilation (adjusting parametres of ventilation,
changing type of mask, adding chin strap, etc.).
When the number of hospital admissions and the total
days spent in hospital in the year prior to NIV was compared
with figures for the year after NIV was initiated we observed
a significant decrease (paired T-test) in both parameters:
number of admissions per patient decreased from 2.21(2.4)
to 0.45(0.6), Po0:0001 and hospital stay decreased from
24.6 (26) to 5.3 (8.9) days, Po0:001.
Survival
In December 2005, 19 patients (50%) were alive and 19
patients died: 11 (58%) due to progression of respiratory
failure, 1 due to empyema and 2 to cardiac insufficiency; 5
patients (26%) died at home and information available was
insufficient to determine the cause of death. The poorest
survival was observed in the ALS patients, with a median of
10.9 (2.34) months, significantly lower than the other
diagnostic groups (log-rank, P ¼ 0:0013). Median survival
for non-ALS patients was 58.5 (4.8) months (Fig. 2).
Discussion
NIV proved to be a very effective therapy in our elderly
population; it provided a highly significant, long-lasting
improvement in arterial blood gases and led to a decrease in
hospital admissions and length of hospital stay in the year
after treatment initiation. Our results are in accordance
with Janssens et al.’s8 study in 6 patients. Moreover, in spite
of the mean age in our study group, the level of hypercapnic
respiratory failure and the comorbidity observed at the
initiation of NIV, survival was surprisingly long, with a
median of almost 5 years, except in ALS patients. A shorter
survival in ALS patients is not unexpected, especially whenbulbar impairment is present12 as was the case in two of our
patients who died.
Owing to the progressive increase in life expectancy and
the lower birth rate in developed countries in recent years,
the absolute number of elderly has grown.13 Moreover,
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E. Farrero et al.1072disability-free life expectancy is increasing and there is a
decrease in the prevalence of severe disability among the
elderly.14 Taken together, these factors are likely to
influence changes in clinical decision-making in the future.15
When considering how far a clinician should go in the
treatment of the elderly, side effects should be carefully
considered as their incidence and severity are frequently
higher the older the patient. In such situations, the risks and
benefits must be estimated prior to the initiation of
treatment. This is not the case, however, in NIV as it is a
safe, well-tolerated treatment and its most frequent
adverse effects are minor. These are generally related to
the nasal mask (regional pain, skin lesions) or to the
ventilator airflow (nasal dryness, conjunctival irritation).6
In our population, as in Janssens et al.’s8 study, no
significant side effects were reported and their incidence
was very similar than the observed in our general popula-
tion.10 So in our experience, the incidence and severity of
side effects are not related to age.
Another aspect to consider in the elderly is the difficulty
that may be encountered when treatment is complex.
Physicians may consider that efficacy of therapy could be
limited in this group of patients because of higher intoler-
ance, lower compliance or incorrect application of therapy.
As a result, NIV therapy may not be considered an option as
first choice treatment and less effective but simpler
treatment may be given. This is likely what occurred in
almost 50% of our patients who were treated with home
oxygen therapy before they were finally referred to our
center for NIV assessment due to their clinical and blood gas
deterioration and frequent hospital admissions. After initia-
tion of NIV, a significant improvement in gas-exchange and a
decrease in hospital admissions was observed, and home
oxygen therapy was successfully discontinued in several
patients.
The initial level of tolerance observed in our study was
acceptable, although five patients (11%) finally abandoned
domiciliary NIV. This percentage is significantly higher than
that observed in the younger population in our center (4%,
unpublished data), but is similar to data from the general
population treated with NIV reported in other studies, such
as the 10% in Rey et al.’s study,16 and considerably lower
than the 35% in Criner et al.’s17 report. However, it should
be kept in mind that 71% of Criner’s population had COPD
diagnosis17 and NIV is still considered controversial treat-
ment for this entity in the stable situation.18 All patients in
our study however, had clearly established criteria for NIV
according to clinical diagnosis and hypercapnia, as we
considered candidates to home NIV only patients with
restrictive extrapulmonary disease but not COPD.
Like Rey et al., we found no significant differences
between patients who discontinued NIV and patients who
continued on NIV, so no predictive factors of tolerance and
compliance could be identified prior to treatment.
Compliance was also good in this elderly population; 8.3
(3.1) h/day, comparable to data reported in the large series
of domiciliary ventilation which included patients of all
ages: 7.88 (2.1) h/day in the Simonds and Elliot’s study19 and
9 (2) h/night and 1.5 (2) h/day in the study of Leger et al.1
In conclusion, our results show the efficacy of NIV in the
elderly. We observed an improvement in arterial blood gases
and nocturnal desaturations, a decrease in hospital admis-sions and length of hospital stay and a median survival of
almost 5 years. Furthermore, compliance and tolerance
were comparable to results in the general population. As no
predictive factors of continuation of domiciliary therapy
were found, we propose a trial period of NIV for all patients
fulfilling the indication criteria, irrespective of age.References
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